By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


Key Statistics

Ownership: Public

Web Site: Bristol-Myers Squibb
Symbol: BMY



PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead (Seattle, WA) 

Company News
Bristol-Myers Squibb (BMY) And AbbVie (ABBV) Receive FDA Approval Of Empliciti (Elotuzumab) For The Treatment Of Patients With Multiple Myeloma Who Have Received One To Three Prior Therapies 12/1/2015 11:51:49 AM
Bristol-Myers Squibb (BMY) To Present New Data Across Multiple Blood Cancers At The 57th Annual Meeting & Exposition Of The American Society of Hematology 11/30/2015 10:10:50 AM
FDA Passes On Expanded Approval of Bristol-Myers Squibb (BMY)'s Opdivo 11/30/2015 6:22:38 AM
Bristol-Myers Squibb (BMY) Receives FDA Approval For Opdivo (Nivolumab), The Only Treatment To Deliver Significant Overall Survival In Advanced Renal Cell Carcinoma Vs. A Standard Of Care, In Patients Who Have Received Prior Anti-Angiogenic Therapy1 11/24/2015 12:24:00 PM
Bristol-Myers Squibb (BMY) Announces U.S. FDA Approval For Opdivo (Nivolumab) As A Single Agent For The Treatment Of Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma 11/24/2015 12:20:27 PM
LSP And Bristol-Myers Squibb (BMY) Enter Into Strategic Collaboration For Life Sciences Innovation In Europe 11/24/2015 6:14:08 AM
The Medicines Patent Pool Signs Licence With Bristol-Myers Squibb (BMY) To Increase Access To Hepatitis C Medicine Daclatasvir 11/23/2015 8:17:12 AM
Bristol-Myers Squibb (BMY) Release: New Long-Term Data On Opdivo And The Opdivo + Yervoy Regimen Shows Survival Benefit Across Lines Of Therapy In Advanced Melanoma 11/19/2015 12:21:38 PM
Bristol-Myers Squibb (BMY) Release: Data From ALLY-3+ Trial Investigating Daklinza (Daclatasvir) In Combination With Sofosbuvir And Ribavirin In Chronic Hepatitis C Genotype 3 Patients With Advanced Fibrosis Or Cirrhosis Presented At American Association for Study of Liver Diseases 11/16/2015 10:48:42 AM
Bristol-Myers Squibb (BMY) To Present New Data For Opdivo (nivolumab) in Advanced Melanoma, As Monotherapy And In Combination With Yervoy (ipilimumab), At The Society For Melanoma Research 2015 International Congress 11/12/2015 11:58:29 AM